E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Food Hypersensitivity
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Trial Timeline
Oct 1, 2009 → Oct 1, 2010
NCT ID
NCT00850668About E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 is a phase 1 stage product being developed by Allergy Therapeutics for Food Hypersensitivity. The current trial status is completed. This product is registered under clinical trial identifier NCT00850668. Target conditions include Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity.
What happened to similar drugs?
2 of 3 similar drugs in Food Hypersensitivity were approved
Approved (2) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00850668 | Phase 1 | Completed |
Competing Products
17 competing products in Food Hypersensitivity